Doxazosin Tablet
Product Images NDC 50090-7803
View Photos of Packaging, Regulatory Labels, and Product Appearance
Product Visual Gallery
This gallery contains 4 technical images submitted to the FDA as part of the official labeling for Doxazosin (NDC 50090-7803). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.
As provided by A-s Medication Solutions, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.
Product Images & Figures Index
Image (Image 2)
This text provides data from multiple studies evaluating the impact of Doxazosin mesylate on maximum flow rate and symptom score in individuals with BPH. The studies involve titration to different dosages and durations of treatment, presenting changes in baseline measurements and endpoint scores. Additionally, the studies mention the use of questionnaires to assess symptoms and specify the timing of efficacy assessments post-dosage. Overall, the text highlights the efficacy of Doxazosin mesylate in improving flow rate and symptom scores compared to a placebo group.*
1 (Image 3)
This is a comparison of the mean change in total symptom score and the mean increase in maximum urinary flow rate from baseline over the duration of treatment in weeks. The data includes results for a group of 47 subjects, with comparisons made to placebo and baseline values. The study also indicates the doxazosin titration to a maximum of 8 mg. Levels of statistical significance (p < 0.05) are highlighted for comparisons to placebo and baseline values.*
Label Image (Lbl500907803)
* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.